Astria rises on FDA's orphan drug tag for its genetic disorder treatment

Astria Therapeutics

30/09/2024 16:43

** Shares of drug developer Astria Therapeutics  ATXS.O 
rise about 3% to $11.45
    ** Co receives FDA orphan drug designation for navenibart
for treatment of hereditary angiodema
    ** Angiodema causes swelling of arms, face, legs and
intestinal tract 
    ** Orphan drug tag based on early-to-mid-stage trial, in
which drug showed reduced monthly swelling attack rates by 90%
to 96% when dosed once or twice over 6 months
    ** Co expects to get additional results from trial in Q4 and
progress navenibart into late-stage trial initiating in Q1 2025 
        ** Including session's move, stock up ~47.3% YTD
  




 (Reporting by Sruthi Narasimha Chari and Christy Santhosh)
 ((Sruthinarasimha.chari@thomsonreuters.com))